Skip to Content

View Additional Section Content

Ellis Fischel Cancer Center and MD Anderson

Clinical Trials

Through the clinical trials program at Ellis Fischel Cancer Center, patients might have access to treatments years before they become widely available. "The reason we are where we are today is because of clinical trials," said C. Daniel Kingsley, MD, FACP, Ellis Fischel oncologist and director of the trials program. "For some patients, these treatments are game changers because having that access a year or even two years before anyone else can make a huge difference for a cancer patient. You are giving them a head start." For Dr. Kingsley, imagining a world without cancer means a future where treatments for each patient become even more personalized.

"I can see a future where we can examine your specific cancer, then examine its gene expression and tailor the treatment specifically to the genetic makeup. Maybe it’s a vaccine or maybe it’s antibodies, but we are getting closer to a world of personalized treatments." Even if we never reach a perfect world without cancer, Dr. Kingsley said he can envision a world where the survival rates for cancer improve and treatments become less toxic to the body. Right now, he’s proud of the work going on at Ellis Fischel.

"We have an incredible amount of brain power under one roof to create the best treatment plan for each patient," Kingsley said. "Not only that, but we are collaborating with researchers across the University of Missouri campus to better understand the how cancer behaves and reacts to treatments."

Clinical trials are research studies that involve people. They are the final step in a long process that begins with research in a lab and animal testing. Many treatments used today are the result of past clinical trials.

Ellis Fischel Cancer Center physicians and staff ensure that all of our patients receive the best care. This means if we ask you or a loved one to participate in a clinical trial, we have good reason to believe that the new treatment(s) will help and we see promise and potential in the new treatment options. These new treatments could become the new standard of care and we want only the best for our patients.

Brain

**No Trials Available at this time.

Breast

  • CIRB-NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall & Regional Nodal XRT& Post-Lumpectomy Regional Nodal XRT in Patients w/Positive Axially Nodes before Neoadjuvant Chemotherapy who convert to Pathologically Negative Axillary Nodes after Neoadjuvant Chemotherapy. NCT# 01872975
  • CIRB-S1207: Phase III Randomized, Controlled-Placebo Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy+/-One Year of Everolimus in Patients w/High-Risk, Hormone Receptor-Positive & HERS/neu Negative Breast Cancer. NCT# 01674140
  • CALGB 40903: Phase II Study of Neoadjuvant Letrozole for Women w/Estrogen Receptor Positive Ductal Carcinoma Situ (DCIS). NCT# 01439711

  • CIRB-A011106: Alternate approaches for clinical stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant Treatment (ALTERNATE) in Postmenopausal women: A Phase III Study. NCT# 01953588

  • CIRB-NSABP B-52: A Randomized Phase III Trial Evaluating Pathologic completed Response Rates in Patients w/Hormone Receptor-Positive, HER2 Positive, Large Operable & Locally Advanced Breast Cancer Treated w/Neoadjuvant Therapy of Docetaxel, Carboplatin Trastuzumab, & Pertuzumab (TCHP) w/wo Estrogen Deprivation. NCT# 02003209

  • Astra-Zeneca D0819C00003: A Phase III, Open Label, Randomized, Controlled, Multi-Centre Study to assess the efficacy & safety of Olaparib Monotherapy vs. Physician’s Choice Chemotherapy in the Treatment of Metastatic Breast Cancer patients w/germline BRCA ½ Mutations. NCT# 02000622

  • Esiai Inc-E7389-A001-303: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-line Therapy for locally Recurrent or Metastatic Breast Cancer. NCT# 02037529

  • SWOG-1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women w/Early Stage Breast Cancer. NCT# 01598298

  • ECOG 2112 A Randomized Phase III Trial of Endocrine Therapy + Entinostat/Placebo in Postmenopausal Patients w/ Hormone Receptor-Positive Advanced Breast Cancer. NCT# 02115282

  • Alliance A011203 A Randomized, Phase II Trial of Tamoxifen vs. Z-Endoxifen HCI in Postmenopausal Women w/Estrogen Receptor Positive, HER2 Negative, Breast Cancer. NCT# 02311933

Cancer Control

**No Trials Available at this time.

Gastrointestinal (GI)

Colon

  • Biothera PRIMUS: A Phase III open-label, Randomized, Multicenter Study of Imprime PGG in Combination w/Cetuximab in subject w/Recurrent or Progressive KRAS Wild Type Colorectal Cancer. NCT# 010309126
  • CALGB 80702: Phase III Trial of 6 vs. 12 Treatments of Adjuvant FOLFOX + Celecoxib or Placebo for Patients w/Resected stage III Colon Cancer. NCT# 01150045

Renal

  • ALLIANCE-A021202: Prospective Randomized Phase II Trial of Pazopanib (NSC#737754, IND# 75648) vs. Placebo in Patients w/Progressive Carcinoid Tumors. NCT# 01841736

Genitourinary GU

Prostate

  • SWOG S1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 w/Androgen Deprivation Therapy + Bicalutamide in Patients w/Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer. NCT# 01809691
  • CIRB-A031201: Phase II of Enzalutamide (NSC#766085) vs. Enzalutamide, Abiraterone & Prednisone for Castration Resistant Metastatic Prostate Cancer. NCT# 01949337

Gynecological Oncology (GYN)

Cervical

  • GOG-263: Randomized phase III study of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk Stage I-IIA Cervical Cancer Treated w/initial Radical Hysterectomy & Pelvic Lymphadenectomy. NCT# 01101451

Endometrial

  • GOG-0238: Randomized Trial of Pelvic Irradiation w/wo Concurrent Weekly Cisplatin in Patients w/Pelvic only Recurrence or Carcinoma of the Uterine Corpus. NCT# 00492778

Head and Neck

Metastatic

  • CIRB-RTOG 1216: Randomized Phase II/III Trial of Surgery & Postoperative Radiation Delivered w/ Concurrent Cisplatin vs. Docetaxel & Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck. NCT# 01810913

Hematology

LEUKEMIA/AML- Untreated

  • CIRB-SWOG S1203: Randomized Phase III Study of Standard Cytarabine+Daunorubicin (7+3) Therapy or Idarubicin w/ High Dose Cytarabine (IA) vs. IA w/ Vorinostat (NSC-701852) (IA+V) in Younger Patients w/Previously untreated AML. NCT# 01802333

  • CIRB-ECOG E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment w/Lenalidomide (Revlimid) Alone & in Combination w/Epoetin Alfa (Procrit) in subjects w/low-or Intermediate-1 Risk MDS & Symptomatic Anemia. NCT# 00843882

  • CIRB-A041202: Randomized Phase III Study of Bendamustine+ Rituximab vs. Ibrutinib + Rituximab vs. Irbutinib Alone in Untreated Older Patients (>/=65 Years Of age) with CL. NCT# 01886872

LYMPHOMA

  • CALGB-50904: Randomized Phase III Trial of Ofatumumab & Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239, IND#58443) & Bendamustine in Pt’s w/Untreated Follicular Lymphoma. NCT# 01286272

  • ECOG-E1411: Randomized Phase II Four Arm Study in Pt’s > 60 w/Previously Untreated Mantle Cell Lymphoma of Therapy w/: Arm A= Rituximab+Bendamustine Followed By Rituximab Consolidation(RBR); Arm B= Rituximab+Bendamustine+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RBVLR) or Arm D=Rituximab+Bendamustine+Bortezomib Followed By Lenalidomide+Rituximab Consolidation (RBV>LR). NCT# 01415752

  • NCIMET-9177: Phase II, Dose-Adjusted EPOCH+/-Rituximab in Adults w/untreated Burkitt Lymphoma, C-Myc positive Diffuse Large B Cell Lymphoma & Plasmablastic Lymphoma **DLBCL Treatment Arm has closed trial is still open to patients with untreated Burkitt Lymphoma. NCT# 01092182

  • Celgene: Phase 3b Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. NCT# 01996865

Leukemia

  • Genentech Roche #200301: A Phase II, Open-Label Study of Obinutuzumab + Bendamustine (BG) in Patients w/Previously Untreated CLL. NCT# 02320487

Lung

SCLC Limited

  • CIRB-SWOG S1400: Phase II/III Biomarker-Driven Master Protocol for 2nd line Therapy of Squamous Cell Lung Cancer. NCT# 02154490 **sub-study Arm E is closed. **Arm E only has closed to Accrual on **11/25/14**

  • Newlink-0301: Open-Label, Randomized Phase IIB/III Active Control Study of Second-Line Hyper-Acute (R)-Lung (Tergenpumatucel-Immunotherapy vs. Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer. NCT# 01774578

Skin

Melanoma

  • CIRB - SWOG 1320: Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) & Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma NCT# 02196181

Why Have Clinical Trials?

In cancer, clinical trials are designed to answer questions about new ways to:

  • Treat Cancer
  • Find and diagnose cancer
  • Prevent cancer
  • Manage symptoms of cancer or side effects from its treatment

Studies are designed to answer questions about new treatments or ways of using an existing treatment better.  These trials test many types of treatments, such as new:

  • Drugs or vaccines
  • Ways to do surgery or give radiation therapy
  • Combinations of treatments

Please visit the following link for more information from the National Cancer Institute (NCI) about Clinical Trials:  http://www.cancer.gov/